Task Force Information
Objectives
Consumers, the scientific community, regulators and the food and dietary supplement industry show increasing interest in probiotics and their health benefits. The attention of the task force is thus focused on the understanding of the role of probiotics in health and disease, their mechanisms of action while increasing awareness of their direct/indirect benefits on health.
Task Force Members
| Arthur Ouwehand – Chair | International Flavors & Fragrances (IFF) | R&D Group Manager | FI |
| Geertrui Vlaemynck* – Co-Chair | Institute for Agricultural and Fisheries Research (ILVO) | Scientific Director | BE |
| Bruno Pot | Yakult Europe | Science Director Europe | NL |
| Jonathan Lane | H&H Group | Senior Manager, Global Research | IE |
| David Perez Pascual | Danone Nutricia Research | Team Leader Culture Collection | FR |
| Delphine Saulnier | Novonesis | Science Manager | DE |
| Benjamin Anderschou Holbech Jensen* | University of Copenhagen | Assist. Professor, Head of Nutritional Immunology | DK |
| Erin Quinn | Holland & Barrett | Senior Scientist | UK |
| Vicenta Garcia Campayo | Cargill | Principal Scientist | USA |
* Scientific Advisors
Contact Information
For more detailed information, please contact Maria Tonti at mtonti@ilsieurope.be
Activity Overview
Ongoing Activities
- Probiotic Clinical Study Design
The Expert Group will work on recommendations and a decision tree for designing effective probiotic clinical studies. This initiative will bring together experts from academia, industry, and regulatory bodies to enhance research quality by establishing reporting guidelines, streamlining study design, and developing reliable protocols tailored to the unique nature of live microbes.
The activity will involve a workshop on the 3rd of April 2025, at ILSI Europe office in Brussels. More info for the workshop to be announced soon.
Start date: Q4 2024 - End date: Q2 2025
- Markers of the Gut Microbiota
The group aims to identify key markers for assessing microbiota improvement, focusing on measurable indicators of microbiota composition and activity that are relevant to human health. This activity will address the need for standardized markers to evaluate dietary interventions, combining various indicators for comprehensive evaluation. The activity is shared with the Prebiotics Task Force.
Start date: Q1 2025 - End date: Q2 2026
Upcoming Activities
- Postbiotics for early life nutrition
The Expert group aims to explore the emerging role of postbiotics in infant nutrition through a focused, workshop-style debate involving experts in microbiota, pediatrics, and nutritional science. This initiative will identify key challenges, assess knowledge gaps, and develop recommendations to guide future research and applications. The outcomes will be published to support evidence-based guidance in infant and early childhood health. This is a joint activity with the Early Nutrition and Long-Term Health Task Force.
Start date: Q4 2025 - End date: Q2 2027
Expert Groups
Probiotic Clinical Study Design
Background and Objectives
The aim of this activity is to develop recommendations and a decision tree for designing effective probiotic clinical studies, taking into account the unique characteristics of live microbes. This initiative will gather input from experts in academia, CROs, industry, and regulatory bodies to enhance the quality and outcomes of probiotic research. The objectives include: (1) organizing a consensus workshop to establish proper reporting guidelines, (2) generating a decision tree to streamline study design, and (3) recommending study protocols that ensure control and reliability. The activity will also focus on identifying appropriate study designs for various research purposes and highlighting critical considerations specific to probiotics, including the importance of accurate study reporting.
Output
This activity will result in recommendations/ decision tree to optimize study design, taking into account the unique, live nature of probiotics.
Expert Group Members
| Hania Szajewska | University of Warsaw | PL |
| Adele Costabile | University of Roehampton | UK |
| Marc Benninga | Emma Children’s Hospital, AMC | NL |
| Francisco Guarner | University Hospital Vall d’Hebron | ES |
| Gemma Walton | University of Reading | UK |
| Patricia Sanz Morales | University of Reading | UK |
| Arthur Ouwehand | IFF | FI |
| Jonathan Lane | H&H Group | IE |
| Nikoletta Vidra | Yakult Europe | NL |
| Carolien van Loo-Bouwman | Yili | NL |
Publications
Oldest to Newest
Guidance for Assessing the Probiotics Beneficial Effects: How to Fill the Gap
2010
Monitoring Immune Modulation by Nutrition in the General Population: Identifying and Substantiating Effects on Human Health
2013
British Journal of Nutrition 2013; 110(2):S1-S30. Commissioned by the Nutrition and Immunity and Probiotics Task Forces.
Probiotics, Prebiotics and the Gut Microbiota
2013
ILSI Europe Concise Monograph. 2013:1-32. Commissioned by the Prebiotics and Probiotics Task Forces. Translation available in Portuguese and Japanese.
Human Intestinal Barrier Function in Health and Disease
2016
Clinical and Translational Gastroenterology 2016. 7, e196. Commissioned by the Probiotics Task Force.
Homeostasis of the Gut Barrier and Potential Biomarkers
2016
American Journal of Physiology – Gastrointestinal and Liver Physiology 2017; 312 (3): G171-G193. Commissioned by the Probiotics Task Force.
Multimedia
Completed Expert Groups
Overview of completed activities
- Benefits, challenges, and opportunities with changes in the maternal microbiome before and during pregnancy
- Prediction of individual responses to prebiotics and probiotics intervention (collaboration Prebiotics Task Force)
- Joint nutrition cluster activity on ‘mechanistic insights into the gut-brain axis' in collaboration with Early Nutrition and Long-Term Health; Health Benefit Assessment of Foods; Nutrition, Immunity & Inflammation; Nutrition & Brain Health and Prebiotics Task Forces
- Updated concise monograph - Dietary Probiotics, Prebiotics and the Gut Microbiota in Human Health (collaboration with Probiotics Task Force)
